London, UK – A highly controversial clinical trial investigating the use of puberty blockers in children and young people experiencing gender incongruence is poised to recommence after being cleared by the Medicines and Healthcare products Regulatory Agency (MHRA). The Phase III PATHWAYS trial, spearheaded by King’s College London (KCL), had been halted in February due to concerns regarding participant well-being, sparking significant public debate and protests across the United Kingdom.
The MHRA, in conjunction with KCL, has concluded a thorough scientific dialogue, resulting in an agreement on a modified trial protocol that meets stringent regulatory standards. Concurrently, the Health Research Authority (HRA) has given its approval, affirming the trial’s ethical integrity. This dual approval signifies a critical juncture for the PATHWAYS study, which aims to generate vital evidence on the efficacy and safety of gonadotropin-releasing hormone analogues (GnRHa) in a vulnerable demographic.
The decision to allow the trial to proceed has been met with a mixture of anticipation and ongoing apprehension. Proponents emphasize the urgent need for robust, evidence-based healthcare for young people with gender incongruence, while critics continue to voice concerns about the potential long-term implications of such interventions. The legal landscape surrounding the trial remains active, with a judicial review challenge pending against the MHRA and HRA decisions, focusing on the regulatory processes employed.
A Tumultuous Journey: Chronology of the PATHWAYS Trial
The PATHWAYS trial, identified by its ISRCTN12491684 registration, has been a focal point of intense public and professional discussion since its inception. The initial pause in February 2026 marked a significant interruption, driven by concerns that necessitated a comprehensive review by regulatory bodies.
February 2026: The PATHWAYS trial is abruptly paused by the MHRA. The stated reason revolves around concerns for the well-being of the young participants enrolled in the study. This decision triggers widespread media attention and intensifies the existing public debate surrounding gender-affirming care for minors.
Following the Pause: An intensive period of scientific dialogue ensues between the MHRA and the KCL research team. This process involves detailed examination of the trial’s design, conduct, and the data collected thus far. The MHRA, in parallel, seeks expert advice from the Commission on Human Medicines (CHM) regarding participant safety and the adequacy of proposed safeguards.
Recent Developments: The MHRA and KCL announce an agreement on a modified protocol. This revised protocol incorporates strengthened safeguards designed to enhance participant protection. The HRA independently reviews and approves the trial based on its ethical considerations.
Ongoing Legal Scrutiny: Despite regulatory clearance, the trial faces a judicial review challenge brought against the MHRA and HRA. This legal action is expected to further scrutinize the regulatory decision-making processes, potentially impacting the trial’s commencement date.
Anticipated Commencement: Recruitment for the PATHWAYS trial is currently slated to begin on August 1, 2026, contingent on the resolution of legal proceedings.
Strengthening Safeguards: The Modified Protocol
The core of the MHRA’s approval lies in the meticulously revised trial protocol. These modifications are not superficial but represent a significant enhancement of the safeguards in place to protect the young participants.
Introduction of Minimum Age Requirements: A key amendment is the establishment of a minimum age for entry into the trial. This will be 11 years old for individuals registered as female at birth and 12 years old for those registered as male at birth. This measure aims to ensure that participants are of an age where they can better comprehend the implications of the trial and provide informed consent, alongside parental or guardian agreement.
Enhanced Discontinuation Measures: The modified protocol introduces more clearly defined discontinuation criteria specifically addressing safety concerns. These include:
- Bone Health: Regular monitoring and defined thresholds for potential adverse effects on bone density and development.
- Cognition: Assessment of cognitive function to identify any potential negative impacts.
- Vaginal Bleeding: Specific protocols for monitoring and managing any instances of abnormal vaginal bleeding in participants.
Improved Fertility Preservation Information: Participants and their guardians will receive more detailed and comprehensive information regarding the potential impact of GnRHa on fertility. This includes clear explanations of available fertility preservation options, empowering families with knowledge to make informed decisions.
Strengthened Patient Information: The research team has explicitly stated that patient information materials connected to the trial have been significantly strengthened. This ensures that the information provided is clear, accessible, and accurately reflects the potential risks and benefits of participating in the study.
The PATHWAYS trial investigates the use of gonadotropin-releasing hormone analogues (GnRHa), including medications such as leuprolide acetate and triptorelin. These drugs are designed to temporarily pause the physical changes of puberty. The trial’s primary objective is to provide a robust evidence base for their use in young people experiencing gender incongruence, thereby informing future healthcare practices within the National Health Service (NHS).
Official Responses and Perspectives
The decision to allow the PATHWAYS trial to resume has been accompanied by statements from key stakeholders, each articulating their rationale and outlook.
The PATHWAYS Research Team: A spokesperson for the research team expressed their commitment to participant safety and transparency. "We will always welcome scrutiny of research involving children and young people because their health and safety is paramount," they stated. "Our priority remains to safely and robustly investigate the benefits and risks of puberty suppression for young people with gender incongruence to improve the evidence base and inform NHS healthcare."
Regarding the concerns that led to the pause, the team emphasized: "We have worked extensively and openly with the MHRA to understand and resolve the questions they raised about the PATHWAYS trial in February, which were not based on the emergence of any new scientific evidence. We have strengthened patient information connected to the trial and introduced a minimum age requirement; there are no major changes to the design or conduct of the PATHWAYS trial."
The spokesperson acknowledged the ongoing legal challenge: "Approval of the modified protocol paves the way for the study to begin, subject to the ongoing judicial review challenge to MHRA and HRA decisions, which focuses on their regulatory processes. As a research team, we will engage with this fully and openly."
Professor Sir Jonathan Montgomery, Professor of Health Care Law at University College London (UCL): Offering an academic perspective, Professor Montgomery highlighted the importance of prompt regulatory review and ongoing scrutiny. "It is good that the MHRA and HRA have completed their reviews of the scientific and ethical concerns that have been raised with them about the PATHWAYS clinical trial promptly," he commented. "They have ensured that a modified protocol is in place prior to recruitment. It is encouraging that full regulatory oversight has been possible without unduly delaying the trial. Legal proceedings are expected to provide further scrutiny."
He further added, "It is to be hoped that the court will be able to reach a timely conclusion so that the legal status of the trial is confirmed before the anticipated date for commencement on 1 August. If there are legal issues that the regulators have overlooked, then it is in everyone’s interests that these are clarified as soon as possible."
Context of the Cass Review and Puberty Blocker Ban: The PATHWAYS trial operates within a complex and evolving landscape concerning gender-affirming care for minors in the UK. In 2024, the UK government accepted the findings of the Cass Review, which concluded that there was "currently an unacceptable safety risk" associated with the routine prescribing of puberty blockers to individuals under 18. This led to an indefinite ban on their use in this age group outside of clinical research. The Commission of Human Medicines (CHM) provided an independent report supporting this conclusion.
The existence of this ban underscores the profound significance of the PATHWAYS trial. Its findings are intended to determine whether puberty blockers can be safely and effectively used in children and young people experiencing gender incongruence, potentially informing future clinical practice and policy decisions.
Implications and Future Outlook
The recommencement of the PATHWAYS trial, even with a modified protocol and ongoing legal challenges, carries significant implications for the field of adolescent gender-affirming care.
Evidence Generation: The primary objective of the trial is to generate robust, high-quality evidence on the effects of puberty-suppressing medication. This evidence is crucial for understanding the short-term and potential long-term impacts on quality of life, mental health, physical development, cognitive function, and gender-related distress in young people with gender incongruence. The data gathered could fundamentally shape how such care is provided in the future, either supporting or challenging current clinical guidelines.
Impact on Healthcare Policy: The outcomes of the PATHWAYS trial will undoubtedly influence future healthcare policy in the UK and potentially internationally. If the trial demonstrates clear benefits and manageable risks, it could lead to a re-evaluation of the current restrictions on puberty blockers for under-18s within research settings. Conversely, findings that highlight significant risks or limited benefits would further solidify existing policy.
Public and Professional Discourse: The trial’s continuation is likely to reignite the intense public and professional discourse surrounding gender identity and medical interventions for minors. The controversial nature of the subject matter has already led to significant protests and counter-protests, and the resumption of the trial will ensure this debate remains at the forefront. Open and evidence-based communication will be critical in navigating these complex discussions.
Legal Precedent: The ongoing judicial review of the MHRA and HRA decisions is significant. The court’s ruling could set a precedent for how regulatory bodies assess and approve clinical trials involving controversial or novel treatments, particularly those involving vulnerable populations. The timely resolution of these legal proceedings is seen as essential to confirm the trial’s legal status and allow for its planned commencement.
Global Context: While this is a UK-based trial, its findings will be of interest globally. Many countries grapple with similar questions regarding the use of puberty blockers and other gender-affirming treatments for young people. The PATHWAYS trial’s outcomes could inform international clinical practice and policy debates.
The PATHWAYS trial represents a critical effort to address a complex and sensitive area of healthcare. The coming months will be crucial as the trial navigates its renewed path forward, under the watchful eye of regulators, the scientific community, and a public deeply engaged in the debate. The ultimate success of the trial will be measured not only by its scientific findings but also by its ability to foster a more informed and evidence-based approach to supporting young people experiencing gender incongruence.
About the Author
